GRAd-COV2

GRAd-COV2 is a vaccine candidate for the prevention of COVID-19, the disease caused by the SARS-CoV-2 virus. It is being developed by ReiThera, a biotechnology company based in Italy.

Development

The GRAd-COV2 vaccine is based on a non-replicating adenovirus vector, specifically the gorilla adenovirus (GRAd). The vector carries the gene for the full-length spike protein of SARS-CoV-2. The spike protein is the part of the virus that allows it to enter human cells, and by exposing the immune system to this protein, the vaccine aims to stimulate an immune response that will protect against future infection.

Clinical Trials

Phase 1 clinical trials for GRAd-COV2 began in August 2020, with results indicating that the vaccine was well-tolerated and induced a strong immune response in all participants. Phase 2 trials are currently underway.

Efficacy

While the efficacy of GRAd-COV2 is still being evaluated in clinical trials, preliminary results suggest that it may provide protection against COVID-19. However, more data is needed to confirm these findings and to determine the duration of protection provided by the vaccine.

Safety

The safety profile of GRAd-COV2 is also still being evaluated. In Phase 1 trials, the vaccine was generally well-tolerated, with no serious adverse events reported. Common side effects included pain at the injection site, fatigue, headache, and muscle pain.

Regulation

As of now, GRAd-COV2 has not yet been approved for use by any regulatory authority. The vaccine is currently in the clinical trial phase, and its approval will depend on the results of these trials.

See Also

• COVID-19 vaccine
• COVID-19 pandemic
• SARS-CoV-2
• Vaccine

References

<references />

This article is a stub related to pharmacology. You can help WikiMD by expanding it!